A newly published review by Kyle Marra, MD, PhD at the Shiley Eye Institute provides a timely and comprehensive synthesis of current strategies and future directions in the management of retinopathy of prematurity (ROP). This manuscript, created in collaboration with senior author Shira Robbins, MD, Eric Nudleman, MD, PhD and Jimmy Chen, MD , was published in Clinical and Experimental Ophthalmology and is entitled, "ROP Management in the Anti-VEGF Era: Evolving Global Paradigms, Persistent Challenges, and Our AI-Assisted Future." The report offers up-to-date treatment paradigms, comments on new challenges in disease management, and highlights efforts to improve long-term outcomes and global screening strategies using artificial intelligence (AI).
The benefits and limitations of current anti-VEGF therapeutics and emerging treatment modalities are discussed alongside ongoing management challenges such as persistent avascular retina, adult ROP, and delayed reactivation. The review covers innovations in imaging, telemedicine, and AI-based tools and their proposed applications toward improve screening workflows worldwide. Also addressed is the need for longitudinal follow-up in a global registry to track real-world outcomes in order to improve equity in ROP care.
To complement the article, the authors produced a video abstract, summarizing key take-home points. The video is intended to reach a broad audience of clinicians, researchers, and public health workers in their effort to reduce preventable childhood blindness globally.
Shiley Eye Institute Physicians on retinopathy of prematurity
Kyle Marra, MD, PhD
Jimmy Chen, MD
Eric Nudleman, MD, PhD
Shira Robbins, MD
Manuscript URL:
https://onlinelibrary.wiley.com/doi/full/10.1111/ceo.14598
